Eighty-one lupus patients at eight U.S. centers were enrolled in a placebo-controlled Phase 2 trial of mesenchymal stromal cells led by MUSC, with efficacy data now under analysis.
MUSC produced all trial cells in its Clean Cell Facility, and investigators said no serious adverse effects were tied to the infusions, reinforcing the therapy's safety profile.
The MSC approach aims to modulate rather than suppress the immune system, offering a potential option for patients whose standard lupus treatments have failed or lost effectiveness.
MUSC is also extending its long-running cellular therapy infrastructure into rheumatology, pairing oncology CAR-T experience with lupus expertise and building a larger facility to double production capacity.
Researchers said cellular therapies remain early in autoimmune disease, but MSCs and CAR-T could help shift lupus care toward more targeted, individualized treatment.
Will the high cost of these revolutionary therapies make a cure for autoimmune diseases accessible only to the wealthy?
As therapies 'reset' the immune system, what are the unforeseen risks of permanently altering our body's natural defenses?
MUSC’s Phase 2 MSC Therapy for Lupus: Current Status, Scientific Rationale, and Patient Impact (2026)
Overview
The MUSC Phase 2 clinical trial is exploring mesenchymal stromal cell (MSC) therapy as a new approach for treating lupus, a complex autoimmune disease. MSCs are carefully prepared from umbilical cords in specialized labs and infused into patients, with their regenerative and immunomodulatory properties believed to help address lupus’s underlying mechanisms. While the trial’s final results and safety data are still awaited, this research highlights a major shift toward cellular therapies, offering hope for patients who have not responded to conventional treatments. The scientific community is closely watching for updates as this innovative therapy progresses.